Trial Profile
A study investigating the rate of incident serious bacterial, viral or opportunistic infection in rheumatoid arthritis patients starting tocilizumab versus TNF inhibitor
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2019
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Abatacept; Tofacitinib; Tumour necrosis factor inhibitors
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 24 Jan 2019 Results published in the Annals of the Rheumatic Diseases
- 21 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting